The FDA has approved the FL-100, the first prescription brain-stimulation device designed for home use in treating depression. Manufactured by Flow Neuroscience, the device is designed for adults 18 and older with moderate to severe major depressive disorder. Clinicians can prescribe it as a stand-alone treatment or alongside antidepressants and therapy. This approval marks a significant shift in mental health treatment, as more than 20 million adults in the U.S. suffer from depression, and roughly one-third do not get sufficient relief from medication or stop taking it due to side effects.
How the Device Works and Clinical Results
The FL-100 uses transcranial direct current stimulation (tDCS), delivering a gentle electrical current to the prefrontal cortex, a region tied to mood regulation and stress response. The system resembles a lightweight headset and pairs with a mobile app. Patients use it at home for about 30 minutes per day while clinicians monitor progress remotely. The FDA’s approval was based on a randomized controlled trial evaluating home use under remote supervision, published in Nature Medicine. After 10 weeks of treatment, participants who received active stimulation experienced an average symptom improvement of 58% compared to a control group, with many users reporting noticeable changes within the first three weeks. Side effects were generally mild and short-term, including skin irritation, redness, headaches, and brief stinging sensations at electrode sites.
Availability and Future Directions
Flow expects the FL-100 to be available to U.S. patients in the second quarter of 2026, requiring a prescription from a licensed healthcare provider. The company notes that over 55,000 people have already used the device across Europe, the U.K., Switzerland, and Hong Kong. Researchers are exploring additional uses for the platform including sleep disorders, addiction, and traumatic brain injury. The approval reflects a growing shift toward tech-based mental health care and at-home neuromodulation approaches.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.foxnews.com/tech/fda-clears-first-at-home-brain-device-depression